Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an “Adjuvant”: An Exploratory Study

Abstract

Abbreviations: CS/CR: Chemosensitivity/Chemoresistance; mTOR: Mammalian Target of Rapamycin; OCT 1: Organic Cation Transporter 1; SCH: Single-Cell Heterogenates; NSCLC: Non-Small Cell Lung Cancer; FSC: Forward Scatter Channel; SSC: Side Scatter Channel; DRUGS: 5FU: 5-Fluorouracil; ART: Artesunate; CIS: Cisplatin; DCA: Dichloroacetate; DOC: Docetaxel; DOX: Doxorubicin; ERL: Erlotinib; LET: Letrozole; LOM: Lomustine; MET: Metformin; MTX: Methotrexate; PEM: Pemetrexed; RAP: Rapamycin; RBV: Ribavirin; TAM: Tamoxifen; TAX: Taxotere; TAR: Tarceva; TMZ: Temozolomide

2 Figures and Tables

Cite this paper

@inproceedings{Bradford2013IndividualizingCU, title={Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an “Adjuvant”: An Exploratory Study}, author={Sherry A . Bradford and Akbar P Ali Khan}, year={2013} }